ZL006 is primarily used in research settings to study its potential therapeutic effects, particularly in the context of neurological disorders. It is known for its role in inhibiting the interaction between nNOS and PSD-95, which is implicated in the pathogenesis of conditions like stroke and neurodegenerative diseases. By disrupting this interaction, ZL006 has shown promise in reducing neuronal damage and improving outcomes in experimental models of ischemic stroke. Researchers are also exploring its potential in mitigating neuroinflammation and protecting against excitotoxicity, making it a compound of interest for developing novel neuroprotective therapies. Its application remains largely confined to preclinical studies, with ongoing investigations to better understand its efficacy and safety profile.